The question, then, is how quickly IMC-C225 can get through the U.S. Food and Drug Administration.
FORBES: Magazine Article
The big prize in ImClone's research pipeline is probably IMC-1121B, which works similarly to Avastin, from Genentech.
FORBES: Icahn Wins, But Bristol Isn't A Total Loser Either
Bristol-Myers says that it's getting 40% of the profits from the drug, IMC-C225, and that the rest will go to ImClone.
应用推荐
模块上移
模块下移
不移动